Zealand Pharma A/S (CHIX:ZEALC) 3-Year Revenue Growth Rate : 6.60% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Zealand Pharma A/S 3-Year Revenue Growth Rate?

Zealand Pharma A/S's Revenue per Share for the three months ended in Dec. 2023 was kr0.40.

During the past 12 months, Zealand Pharma A/S's average Revenue per Share Growth Rate was 169.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 6.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 29.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 4.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Zealand Pharma A/S was 219.60% per year. The lowest was -60.70% per year. And the median was 4.40% per year.

Competitive Comparison of Zealand Pharma A/S's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Zealand Pharma A/S's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma A/S's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's 3-Year Revenue Growth Rate falls into.

Zealand Pharma A/S 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Zealand Pharma A/S (CHIX:ZEALc) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Zealand Pharma A/S 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (CHIX:ZEALC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (CHIX:ZEALc) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (CHIX:ZEALC) Headlines

No Headlines